Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Lexaria Bioscience ( (LEXX) ).
Lexaria Bioscience Corp. announced a $3.5 million registered direct offering priced at-the-market under Nasdaq rules, involving the sale of 2,661,600 shares of common stock and concurrent issuance of unregistered warrants. The proceeds will support Lexaria’s research and development, working capital, and general corporate purposes, potentially strengthening its market position and advancing its innovative drug delivery technologies.
The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, known for its patented DehydraTECH technology. This platform enhances the oral delivery of various drugs by improving bio-absorption, reducing side effects, and facilitating more effective delivery across the blood-brain barrier. The company operates a licensed in-house research laboratory and holds a significant intellectual property portfolio with 56 patents granted worldwide.
Average Trading Volume: 577,635
Technical Sentiment Signal: Sell
Current Market Cap: $29.78M
For detailed information about LEXX stock, go to TipRanks’ Stock Analysis page.